Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
IPO Year: 2015
Exchange: NASDAQ
Website: natera.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/13/2025 | $251.00 | Outperform | RBC Capital Mkts |
| 1/23/2025 | $200.00 | Overweight | Barclays |
| 6/3/2024 | $142.00 | Buy | Jefferies |
| 4/8/2024 | $117.00 | Buy | Craig Hallum |
| 2/20/2024 | $68.00 → $85.00 | Strong Buy → Outperform | Raymond James |
| 12/29/2023 | $75.00 → $85.00 | Buy | BTIG Research |
| 12/14/2023 | $70.00 | Buy | Guggenheim |
| 12/13/2023 | $70.00 | Outperform | Wolfe Research |
| 11/13/2023 | $68.00 | Outperform → Strong Buy | Raymond James |
| 9/28/2023 | $48.00 | Mkt Perform | Bernstein |
Fastest customizable press release news feed in the world
Topline results from the trial show that Signatera-positive patients treated with atezolizumab (Tecentriq®) had statistically significant and clinically meaningful improvements in disease-free survival and overall survival IMvigor011 is the first prospective phase III study in muscle-invasive bladder cancer to read out that uses a personalized, ctDNA MRD*-guided approach Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced positive topline results from the randomized, phase III IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC). The trial is sponsored by Genentech, a member of the Roche Group. IMvigor011 utilizes the Sign
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025. Recent Financial Highlights Generated total revenues of $546.6 million in the second quarter of 2025, compared to $413.4 million in the second quarter of 2024, an increase of 32.2%. Product revenues grew 32.3% over the same period. Generated a gross margin of 63.4% in the second quarter of 2025, compared to a gross margin of 58.8% in the second quarter of 2024. Processed approximately 853,100 tests in the second quarter of 2025, compared to approximately 760,300 tests in the second quarter of 2024, an increase of 12.
Launch supported by strong assay performance in first milestone readout of the landmark EXPAND clinical trial Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test (NIPT) for inherited conditions. When a pregnant patient is identified as a carrier of a recessive single-gene condition, medical guidelines recommend partner testing in order to determine the risk for the baby to be affected by the condition1; however, in some cases the biological father is unavailable for testing. The Fetal Focus test was designed to address this unmet need. Now if a pregnant patient tests p
High-impact datasets across heart, kidney and lung at WTC follows two major publications in the American Journal of Transplantation in the last three months Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present several new datasets at the 2025 World Transplant Congress (WTC), taking place August 2 - 6 in San Francisco, CA. The presentations span kidney, heart and lung transplantation and represent one of the most comprehensive collections of data on Natera's Prospera test to date. Highlights include five oral presentations and 11 poster sessions featuring evidence from high-impact studies that support the use of Natera'
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30, 2025, after the market closes on August 7, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's Second Quarter 2025 Financial Results Date: August 7, 2025 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID: 7684785 Webcast:
Study utilizes Signatera to identify HR+, HER2-negative breast cancer patients for de-escalation of neoadjuvant chemotherapy Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the TEODOR trial (Neoadjuvant TrEatment Optimization driven by ctDNA and endOcrine Responsiveness). TEODOR is a Phase II, multicenter, randomized controlled trial (RCT) that aims to replace chemotherapy with endocrine therapy prior to surgery for a subset of women with hormone receptor-positive (HR+), HER2-negative breast cancer, who are endocrine responsive and test negative with Signatera. Sponsored by the Austrian Breast & Colorectal Cancer Study G
First prospective, multi-center trial to examine how dd-cfDNA can be used in post-rejection patient management Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, today announced that the American Journal of Transplantation published findings from the PEDAL study. PEDAL is the first prospective multi-center trial evaluating longitudinal trends of donor-derived cell-free DNA (dd-cfDNA) to determine the prognostic ability of Prospera in assessing outcomes following kidney transplant rejection. PEDAL enrolled 488 kidney transplant recipients from 28 participating U.S. and international transplant centers over 4 years. 66 patients with biopsy-proven
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latitude™ MRD assay, which were presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI). The clinical performance of the assay was analyzed in a cohort of ~200 patients (>1,300 plasma samples) with resectable stage I-IV colorectal cancer. Samples were derived from the GALAXY arm of the CIRCULATE-Japan study, one of the largest and most comprehensive prospective studies of MRD testing in resectable CRC. Key results include: Excellent clinical sensitivity to recurrence: The Latitude assay detected recur
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) in Barcelona, Spain. These presentations reinforce the strong clinical and economic utility of Signatera™ monitoring across colon and rectal cancers (CRC), as well as new clinical validation data on its tissue-free MRD assay. Signatera in CRC surveillance Data on >3,000 CRC patients will be shared in an oral presentation, concluding that adding Signatera ctDNA* monitoring to the current standard of care in surveillance can better identify patients who are candidates for metastasis-directed t
Broad coverage, inclusive of all previously covered Signatera indications Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medicare under LCD L38779. This coverage decision applies to Medicare beneficiaries with colorectal cancer, breast cancer, bladder cancer, ovarian cancer, lung cancer, and pan-cancer immunotherapy monitoring, mirroring the pre-existing coverage for Signatera. The coverage determination was supported by robust evidence on the validity of the genome-based assay, leveraging the extensive body of literature validating Signatera in over 100 published clinical
SCHEDULE 13G/A - Natera, Inc. (0001604821) (Subject)
10-Q - Natera, Inc. (0001604821) (Filer)
8-K - Natera, Inc. (0001604821) (Filer)
144 - Natera, Inc. (0001604821) (Subject)
144 - Natera, Inc. (0001604821) (Subject)
SCHEDULE 13G/A - Natera, Inc. (0001604821) (Subject)
8-K - Natera, Inc. (0001604821) (Filer)
144 - Natera, Inc. (0001604821) (Subject)
SCHEDULE 13G/A - Natera, Inc. (0001604821) (Subject)
10-Q - Natera, Inc. (0001604821) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
RBC Capital Mkts initiated coverage of Natera with a rating of Outperform and set a new price target of $251.00
Barclays initiated coverage of Natera with a rating of Overweight and set a new price target of $200.00
Jefferies resumed coverage of Natera with a rating of Buy and set a new price target of $142.00
Craig Hallum resumed coverage of Natera with a rating of Buy and set a new price target of $117.00
Raymond James downgraded Natera from Strong Buy to Outperform and set a new price target of $85.00 from $68.00 previously
BTIG Research reiterated coverage of Natera with a rating of Buy and set a new price target of $85.00 from $75.00 previously
Guggenheim initiated coverage of Natera with a rating of Buy and set a new price target of $70.00
Wolfe Research initiated coverage of Natera with a rating of Outperform and set a new price target of $70.00
Raymond James upgraded Natera from Outperform to Strong Buy and set a new price target of $68.00
Bernstein initiated coverage of Natera with a rating of Mkt Perform and set a new price target of $48.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
Live finance-specific insights
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025. Recent Financial Highlights Generated total revenues of $546.6 million in the second quarter of 2025, compared to $413.4 million in the second quarter of 2024, an increase of 32.2%. Product revenues grew 32.3% over the same period. Generated a gross margin of 63.4% in the second quarter of 2025, compared to a gross margin of 58.8% in the second quarter of 2024. Processed approximately 853,100 tests in the second quarter of 2025, compared to approximately 760,300 tests in the second quarter of 2024, an increase of 12.
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30, 2025, after the market closes on August 7, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's Second Quarter 2025 Financial Results Date: August 7, 2025 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID: 7684785 Webcast:
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues grew 37.1% over the same period. Generated a gross margin of 63.1% in the first quarter of 2025, compared to a gross margin of 56.7% in the first quarter of 2024. Processed approximately 855,100 tests in the first quarter of 2025, compared to approximately 735,800 tests in the first quarter of 2024, an increase of
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2025, after the market closes on May 8, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's First Quarter 2025 Financial Results Date: May 8, 2025 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-596-4144 (Domestic) 1-646-968-2525 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/454317205 A webcast replay will be available at
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Recent Financial Highlights Generated total revenues of $476.1 million in the fourth quarter of 2024, compared to $311.1 million in the fourth quarter of 2023, an increase of 53.0%. Product revenues grew 53.9% over the same period. Generated a gross margin of 62.9% in the fourth quarter of 2024, compared to a gross margin of 51.4% in the fourth quarter of 2023. Generated total revenues of $1,696.9 million in the full year of 2024, compared to $1,082.6 million in the full year 2023, an increase of 56.7%
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's Fourth Quarter & Full Year 2024 Financial Results Date: February 27, 2025 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-770-7321 (Domestic) 1-929-201-7101 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/538630796 A webca
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $439.8 million in the third quarter of 2024, compared to $268.3 million in the third quarter of 2023, a record increase of 63.9%. Product revenues grew 64.4% over the same period. Generated a gross margin of 61.8% in the third quarter of 2024, compared to a gross margin of 45.1% in the third quarter of 2023. Processed approximately 775,800 tests in the third quarter of 2024, compared to approximately 626,000 tests in the third quarter of 2023, an
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its third quarter ended Sept. 30, 2024, after the market closes on Nov. 12, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera's Third Quarter 2024 Financial Results Date: Tuesday, Nov. 12, 2024 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID: 7684785 Webc
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $413.4 million in the second quarter of 2024, compared to $261.4 million in the second quarter of 2023, an increase of 58.1%. Product revenues grew 59.3% over the same period. Generated a gross margin of 58.8% in the second quarter of 2024, compared to a gross margin of 45.2% in the second quarter of 2023. Processed approximately 760,300 tests in the second quarter of 2024, compared to approximately 617,200 tests in the second quarter of 2023, an incr
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera's Second Quarter 2024 Financial Results Date: Thursday, Aug. 8, 2024 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-596-4144 (Domestic) 1-646-968-2525 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/455235752 A web
This live feed shows all institutional transactions in real time.
Live Leadership Updates
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G - Natera, Inc. (0001604821) (Subject)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G - Natera, Inc. (0001604821) (Subject)
Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee
Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations
AUSTIN, Texas, May 24, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types. "I am very pleased to welcome Dr. Liu to Natera," said Solomon Moshkevich, general manager of oncology at Natera. "As a highly reg
Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J